Interferon-Induced Fatigue in Patients With Melanoma: A Pilot Study of Exercise and Methylphenidate
Purpose/Objectives: To examine the effect of exercise and methylphenidate on fatigue, functional ability, and cognitive function in patients with melanoma.
Design: Pilot study with comparison to historic controls.
Setting: University-based cancer center.
Sample: 12 patients with melanoma entered and completed the study. The mean age was 44 years.
Method: Eligible patients were recruited before their first dose of interferon-a (IFN-a). Patients were instructed to take 20 mg sustained-release methylphenidate every morning and follow an aerobic exercise program four days a week for 15-30 minutes. Measures included a 12-minute walk, the Schwartz Cancer Fatigue Scale, Trail Maker Forms A and B, Medical Outcomes Study 36 Short Form, body weight, and daily logs. Fatigue scores were compared to usual care historical controls with melanoma receiving only IFN-a.
Main Research Variables: Fatigue, functional ability, and cognitive function.
Findings: 66% adhered to exercise and methylphenidate; all adhered to exercise. Fatigue was lower for the exercise and methylphenidate group than historic controls. Functional ability increased 6% for all patients and 9% for the exercise and methylphenidate group. Cognitive function was stable for the exercise and methylphenidate group. The exercise-only group showed marked cognitive slowing.
Conclusions: The combination of aerobic exercise and methylphenidate may have a positive effect on fatigue, cognitive function, and functional ability. A larger sample size and randomized trial is needed to more rigorously evaluate the results of exercise and methylphenidate alone or in combination.
Implications for Nursing: Although further study is needed, a combination of exercise and methylphenidate may be a practical intervention for patients receiving IFN-a for melanoma.
Albertsen, P.C., Aaronson, N.K., Muller, M.J., Keller, S.D., & Ware, J.E. (1997). Health-related quality of life among patients with metastatic prostate cancer. <i>Urology</i>, 49, 207-216.
Atkinson, A., Barsevick, A., Cella, D., Cimprich, B., Cleeland, C., Donnelly, J., et al. (2000). NCCN practice guidelines for cancer-related fatigue. <i>Oncology</i>, 14(11A), 151-161.
Bernstein, M.L., Despars, J.A., Singh, N.P., Avalos, K., Stansbury, D.W., & Light, R.W. (1994). Reanalysis of the 12-minute walk in patients with chronic obstructive pulmonary disease. <i>Chest</i>, 105, 163-167.
Bruera, E., Miller, M.J., Macmillan, K., & Kuehn, N. (1992). Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. <i>Pain</i>, 48, 163-166.
Capuron, L., Ravaud, A., & Dantzer, R. (2000). Early depressive symptoms in patients with cancer receiving interleukin 2 and/or interferon alfa-2b therapy. <i>Journal of Clinical Oncology</i>, 18, 2143-2151.
Cimprich, B. (1992). Attentional fatigue following breast cancer surgery. <i>Research in Nursing and Health</i>, 15, 199-207.
Cimprich, B. (1998). Age and extent of surgery affect attention in women treated for breast cancer. <i>Research in Nursing and Health</i>, 21, 229-238.
Cimprich, B. (1999). Pretreatment symptom distress in women newly diagnosed with breast cancer. <i>Cancer Nursing</i>, 22, 185-194.
Cooper, K.H. (1968). A means of assessing maximal oxygen intake: Correlation between field and treadmill testing. <i>JAMA</i>, 203, 201-204.
Curt, G.A., Breitbart, W., Cella, D., Groopman, J.E., Horning, S.J., Itri, L.M., et al. (2000). Impact of cancer-related fatigue on the lives of patients: New findings from the fatigue coalition. <i>Oncologist</i>, 5, 353-360.
Dimeo, F.C., Fletcher, S., Lange, W., Mertelsmann, R., & Keul, J. (1997). Effect of aerobic exercise on the physical performance and incidence of treatment-related complications after high-dose chemotherapy. <i>Blood</i>, 90, 3390-3394.
Dimeo, F.C., Stieglitz, R.D., Novelli-Fischer, U., Fetscher, S., & Keul, J. (1999). Effects of physical activity on the fatigue and psychologic status of patients with cancer during chemotherapy. <i>Cancer</i>, 85, 2273-2277.
Dimeo, F.C., Tilmann, M.H.M., Bertz, H., Kanz, L., Mertelsmann, R., & Keul, J. (1997). Aerobic exercise in the rehabilitation of patients with cancer after high dose chemotherapy and autologous peripheral stem cell transplantation. <i>Cancer</i>, 79, 1717-1722.
Giovagnoli, A.R., Del-Pesce, M., Mascheroni, S., Simoncelli, M., Laiacona, M., & Capitani, E. (1996). Trail Making Test: Normative values from 287 normal adult controls. <i>Italian Journal of Neurological Science</i>, 17, 305-309.
Kirkwood, J.M., Strawderman, M.H., Ernstoff, M.S., Smith, T.J., Borden, E.C., & Blum, R.H. (1996). Interferon alpha-2b adjuvant therapy of highrisk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684. <i>Journal of Clinical Oncology</i>, 14, 7-17.
Larson, J.L., Covey, M.K., Vitalo, C.A., Alex, C.G., Patel, M.J., & Kim, M.J. (1996). Reliability and validity of the 12-minute distance walk in patients with chronic obstructive pulmonary disease. <i>Nursing Research</i>, 45, 203-210.
McHorney, C.A., Ware, J.E., & Raczek, A.E. (1993). The MOS 36-item short form health survey (SF-36): Psychometric and clinical tests of validity in measuring physical and mental health construct. <i>Medical Care</i>, 31, 247-263.
Meyers, C.A. (1999). Mood and cognitive disorders in patients with cancer receiving cytokine therapy. <i>Advances in Experimental Medical Biology</i>, 461, 75-81.
Meyers, C.A., & Weitzner, M.A. (1995). Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous system. <i>Current Opinion in Oncology</i>, 7, 197-200.
Meyers, C.A., Weitzner, M.A., Valentine, A.D., & Levin, V.A. (1998). Methylphenidate therapy improves cognition, mood and function of brain tumor patients. <i>Journal of Clinical Oncology</i>, 16, 2522-2527.
Mock, V., Burke, M.B., Sheehan, P., Creaton, E.M., Winningham, M.L., McKenney-Tedder, S., et al. (1994). A nursing rehabilitation program for women with breast cancer receiving adjuvant chemotherapy. <i>Oncology Nursing Forum</i>, 21, 899-907.
Mock, V., Dow, K.H., Meares, C.J., Grimm, P.M., Dienemann, J.A., Haisfield-Wolfe, M.E., et al. (1997). Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. <i>Oncology Nursing Forum</i>, 24, 991-1000.
National Cancer Institute. (2000). PDQ: Supportive care-Fatigue. Retrieved March 15, 2000, from <a target="_blank" href='http://www.icic.nci.nih.gov/climpdq/supportive/Fatigue.html'>http://www....
Novartis Pharmaceuticals. (2001). <i>Ritalin®</i> [Package insert]. Basel, Switzerland: Author.
Olin, J., & Masand, P. (1996). Psychostimulants for depression in hospitalized patients with cancer. <i>Psychosomatics</i>, 37, 57-62.
Pavol, M.A., Meyers, C.A., Rexer, J.L., Valentine, A.D., Mattis, P.J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. <i>Neurology</i>, 45, 947-950.
Portenoy, R.K. (1989). Use of methylphenidate as an adjuvant to narcotic analgesics in patients with advanced cancer. <i>Journal of Pain and Symptom Management</i>, 4(Suppl. 3), 2-4.
Reitan, R.M. (1955). The relation of the Trail Making Test to organic brain damage. <i>Journal of Consulting Psychology</i>, 19, 393-394.
Reitan, R.M. (1958). The validity of the Trail Making Test as an indicator of organic brain damage. <i>Perceptual and Motor Skills</i>, 9, 120-127.
Reitan, R.M., & Wolfson, D. (1992). Conventional intelligence measurements and neuropsychological concepts of adaptive abilities. <i>Journal of Clinical Psychology</i>, 48, 521-529.
Schwartz, A.L. (1997). Minimally important clinical differences in fatigue. Unpublished raw data.
Schwartz, A.L. (1998). Patterns of exercise and fatigue in physically active cancer survivors. <i>Oncology Nursing Forum</i>, 25, 485-491.
Schwartz, A.L. (1999). Fatigue mediates the effects of exercise on quality of life in women with breast cancer. <i>Quality of Life Research</i>, 8, 529-538.
Schwartz, A.L. (2000). Daily fatigue pattern and effect of exercise in women with breast cancer receiving chemotherapy. <i>Cancer Practice</i>, 1, 16-24.
Schwartz, A.L., & Meek, P. (1999). Additional content validity of the Schwartz Cancer Fatigue Scale. <i>Journal of Nursing Measurement</i>, 7, 35-45.
Stahl, S.M. (1998). Basic psychopharmacology of antidepressants part 1: Antidepressants have seven distinct mechanisms of action. <i>Journal of Clinical Psychiatry</i>, 59, 262-266.
Valentine, A.D., Meyers, C.A., Kling, M.A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects of interferon-alpha therapy. <i>Seminars in Oncology</i>, 25(Suppl. 1), 39-47.
van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., Wall, E., Droo-gleever-Fortuyn, M.E., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High dose versus standard dose chemotherapy. <i>Journal of the National Cancer Institute</i>, 90, 210-218.
Weitzner, M.A., Meyers, C.A., & Valentine, A.D. (1995). Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. <i>Journal of Neuropsychiatry and Clinical Neuroscience</i>, 7, 347-350.
Wilwerding, M.B., Loprinzi, C.L., Mailliard, J.A., O'Fallon, J.R., Miser, A.W., van Haelst, C., et al. (1995). A randomized, crossover evaluation of methylphenidate in patients with cancer receiving strong narcotics. <i>Supportive Care in Cancer</i>, 3, 135-138.